Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
OBJECTIVE
Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc). This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study.


METHODS
SSc patients (64 limited; 94 diffuse) exhibiting dyspnoea on exertion, restrictive pulmonary function and evidence of alveolitis on bronchoalveolar lavage and/or high-resolution computed tomography (HRCT) were randomised to receive cyclophosphamide (CYC) or placebo and serially evaluated over 12 months.


RESULTS
Baseline measures of alveolitis, dyspnoea and pulmonary function were similar in limited and diffuse SSc. However, differences were noted with respect to HRCT-scored fibrosis (worse in limited SSc), and to functional activity, quality of life, skin and musculoskeletal manifestations (worse in diffuse SSc) (p<0.05). When adjusted for the baseline level of fibrosis, both groups responded similarly to CYC with regard to lung function and dyspnoea (p<0.05). Cyclophosphamide was also associated with more improvement in skin score in the diffuse disease group more than in the limited disease group (p<0.05).


CONCLUSIONS
After adjusting for the severity of fibrosis at baseline, CYC slowed the decline of lung volumes and improved dyspnoea equally in the limited and the diffuse SSc groups. On the other hand, diffuse SSc patients responded better than limited patients with respect to improvements in skin thickening.
Clements
Philip J
PJ
Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. pclements@mednet.ucla.edu
Roth
Michael D
MD
Elashoff
Robert
R
Tashkin
Donald P
DP
Goldin
Jonathan
J
Silver
Richard M
RM
Sterz
Mildred
M
Seibold
James R
JR
Schraufnagel
Dean
D
Simms
Robert W
RW
Bolster
Marcy
M
Wise
Robert A
RA
Steen
Virginia
V
Mayes
M D
MD
Connelly
Kari
K
Metersky
Mark
M
Furst
Daniel E
DE
D000328:Adult; D018893:Bronchoalveolar Lavage; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents; D007596:Joints / Q000473:pathology; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011658:Pulmonary Fibrosis / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D012129:Respiratory Function Tests; D045743:Scleroderma, Diffuse / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology; D012594:Scleroderma, Localized / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology; D012595:Scleroderma, Systemic / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D014057:Tomography, X-Ray Computed
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide